Evidence map›Paper›PMID 39698493›Full record

ArticleFrontiers in cell and developmental biology2024

Molecular and metabolomic characterization of hiPSC-derived cardiac fibroblasts transitioning to myofibroblasts.

Raghu Sundaresan Nagalingam, Farah Jayousi, Homa Hamledari, Saif Dababneh, Dina Hosseini, Chloe Lindsay, Ramon Klein Geltink, Philipp F Lange, Ian Michael Dixon, Robert Alan Rose and 2 more

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Raghu Sundaresan NagalingamCellular and Regenerative Medicine Centre, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Farah JayousiCellular and Regenerative Medicine Centre, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Homa HamledariCellular and Regenerative Medicine Centre, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Saif DababnehCellular and Regenerative Medicine Centre, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Dina HosseiniCellular and Regenerative Medicine Centre, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Chloe LindsayDepartment of Biomedical Physiology and Kinesiology, Simon Fraser University, Burnaby, BC, Canada.
Ramon Klein GeltinkCellular and Regenerative Medicine Centre, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Philipp F LangeCellular and Regenerative Medicine Centre, BC Children's Hospital Research Institute, Vancouver, BC, Canada.
Ian Michael DixonInstitute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada.
Robert Alan RoseDepartment of Cardiac Sciences, Cumming School of Medicine, Libin Cardiovascular Institute, University of Calgary, Calgary, AB, Canada.
Michael Paul CzubrytInstitute of Cardiovascular Sciences, St. Boniface Hospital Albrechtsen Research Centre, Winnipeg, MB, Canada.
Glen Findlay TibbitsCellular and Regenerative Medicine Centre, BC Children's Hospital Research Institute, Vancouver, BC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Mechanical stress and pathological signaling trigger the activation of fibroblasts to myofibroblasts, which impacts extracellular matrix composition, disrupts normal wound healing, and can generate deleterious fibrosis. Myocardial fibrosis independently promotes cardiac arrhythmias, sudden cardiac arrest, and contributes to the severity of heart failure. Fibrosis can also alter cell-to-cell communication and increase myocardial stiffness which eventually may lead to lusitropic and inotropic cardiac dysfunction. Human induced pluripotent stem cell derived cardiac fibroblasts (hiPSC-CFs) have the potential to enhance clinical relevance in precision disease modeling by facilitating the study of patient-specific phenotypes. However, it is unclear whether hiPSC-CFs can be activated to become myofibroblasts akin to primary cells, and the key signaling mechanisms in this process remain unidentified. Objective: We aim to explore the notable changes in fibroblast phenotype upon passage-mediated activation of hiPSC-CFs with increased mitochondrial metabolism, like primary cardiac fibroblasts. Methods: We activated the hiPSC-CFs with serial passaging from passage 0 to 3 (P0 to P3) and treatment of P0 with TGFβ1. Results: Passage-mediated activation of hiPSC-CFs was associated with a gradual induction of genes to initiate the activation of these cells to myofibroblasts, including collagen, periostin, fibronectin, and collagen fiber processing enzymes with concomitant downregulation of cellular proliferation markers. Most importantly, canonical TGFβ1 and Hippo signaling component genes including TAZ were influenced by passaging hiPSC-CFs. Seahorse assay revealed that passaging and TGFβ1 treatment increased mitochondrial respiration, consistent with fibroblast activation requiring increased energy production, whereas treatment with the glutaminolysis inhibitor BPTES completely attenuated this process. Conclusion: Our study highlights that the hiPSC-CF passaging enhanced fibroblast activation, activated fibrotic signaling pathways, and enhanced mitochondrial metabolism approximating what has been reported in primary cardiac fibroblasts. Thus, hiPSC-CFs may provide an accurate

Indexed as

arrhythmiacardiac ECMcardiac fibrosiscardiac remodelingfibroblastinduced pluripotent stem cellsmyofibroblast

Identifiers

PMID39698493
PMCPMC11653212

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.